Skip to content
Clinical Trials – home
HungaryBack to Hungary

Clinical trials in Szazhalombatta – page 12

1 121 clinical trials in Szazhalombatta, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Szazhalombatta at a glance
1 121
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 121 trials in Szazhalombatta

Open in trial search

Colitis ulcerative+2

Recruiting

Study of ly4395089 and mirikizumab in adults with moderately to severely active Crohn’s disease

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:LY4395089
  • Sponsor:Eli Lilly & Co.

A Phase 2/3 Study of intravitreal mk-8748 versus aflibercept in adults with neovascular age‑related macular degeneration

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Eyebiotech Limited

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:RO7589655
  • Sponsor:F. Hoffmann-La Roche AG

Asthma

Recruiting

Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Indacaterol Acetate
  • Sponsor:Novartis Pharma AG

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen - Cilag International

Neoplasm

Recruiting

Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Patients Under 18 With Relapsed or Refractory Solid Tumors

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:0–17 years
  • Substances:Ifinatamab Deruxtecan
  • Sponsor:Merck Sharp & Dohme LLC

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

VMX-C001 in Patients Taking Factor Xa Inhibitors Who Need Urgent Surgery or an Invasive Procedure With High Bleeding Risk

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:VMX-C001
  • Sponsor:VarmX B.V.

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen - Cilag International

NHS7108 for Exocrine Pancreatic Insufficiency in Adult Patients

InvestigationalNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Amylase
  • Sponsor:Aimmune Nestle Health Science US R&D LLC

Pumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study of Tirabrutinib, Rituximab, and Temozolomide in Patients with Relapsed/Refractory Primary Central Nervous System Lymphoma

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab
  • Sponsor:Deciphera Pharmaceuticals Inc.

Other cities in Hungary

The busiest research cities in the country

All 73 cities in Hungary

Clinical research in Szazhalombatta

What the registry says about research in the country

01 Respiratory Disease Management

Innovative clinical research focusing on moderate-to-severe asthma, evaluating new therapeutic approaches including dupilumab and amlitelimab for improved lung function and symptom control.

  • Long-term lung function preservation
  • Novel therapeutic evaluation
  • Disease control optimization

Multiple trials are exploring preventive strategies and treatment effectiveness in asthma management.

02 COPD Treatment Innovation

Comprehensive studies examining chronic obstructive pulmonary disease treatments, including evaluation of triple therapy combinations and novel biological agents.

  • Exacerbation reduction strategies
  • Cardiopulmonary outcomes
  • Advanced therapeutic combinations

Research focuses on improving quality of life and reducing disease progression in COPD patients.

03 Advanced Respiratory Therapeutics

Investigation of innovative biological treatments for both asthma and COPD, including studies of benralizumab and itepekimab for patients with severe symptoms.

  • Long-term safety assessment
  • Targeted biological therapies
  • Patient response monitoring

These trials aim to establish new standards in respiratory disease treatment.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.